Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The HAS-BLED score estimates the risk of major bleeding in patients with atrial fibrillation who are on or being considered for anticoagulation therapy. It is meant to be used alongside the [CHA₂DS₂-VASc score](/tools/cha2ds2-vasc) to weigh stroke prevention benefits against bleeding risk. A high HAS-BLED score does not contraindicate anticoagulation but highlights the need for careful monitoring.
Formula: Score = H(1) + A(1+1) + S(1) + B(1) + L(1) + E(1) + D(1+1)
Select yes or no for each of the nine risk factors. Each 'yes' adds 1 point, with renal/liver and drugs/alcohol potentially adding 2 points each.
The calculator sums your points, producing a score from 0 to 9. Higher scores indicate greater annual major bleeding risk.
Review which risk factors can be corrected — blood pressure, labile INR, NSAIDs, alcohol. Addressing these reduces bleeding risk while maintaining anticoagulation benefit.
Cardiologists, internists
Calculate HAS-BLED alongside [CHA2DS2-VASc](/tools/cha2ds2-vasc) when deciding whether to start anticoagulation. Even high bleeding risk usually doesn't preclude anticoagulation.
Physicians, pharmacists
Use the score to have informed conversations about bleeding risk, explaining which factors are modifiable and what monitoring will look like.
Primary care, cardiology clinics
Recalculate yearly as risk factors change. New hypertension, renal disease, or medication changes can increase the score and warrant closer monitoring.
Anticoagulation clinics
Patients with labile INR (score point) need closer INR monitoring or consideration of DOAC switch. The score flags who needs more intensive management.
Surgeons, proceduralists
Quantify bleeding risk before procedures requiring anticoagulation interruption. High HAS-BLED may influence bridging decisions and timing.
Guideline committees, researchers
Compare [CHA2DS2-VASc](/tools/cha2ds2-vasc) against HAS-BLED to assess whether anticoagulation provides net benefit. Most patients benefit even when both scores are elevated.
This is the most important point. Studies consistently show patients with high [CHA2DS2-VASc](/tools/cha2ds2-vasc) and high HAS-BLED still derive net benefit from anticoagulation. The score guides monitoring and risk factor modification, not whether to anticoagulate.
Hypertension (control BP), labile INR (improve TTR or switch to DOAC), drugs (stop unnecessary NSAIDs/antiplatelets), and alcohol (reduce consumption) are all addressable. Fixing these reduces bleeding risk without stopping anticoagulation.
The labile INR criterion was developed for warfarin. For patients on DOACs, this point doesn't apply since there's no INR to monitor. Some experts suggest scoring 0 for this criterion in DOAC patients.
Score a point for chronic dialysis, renal transplantation, or serum creatinine ≥2.3 mg/dL (200 µmol/L). Moderate CKD alone may not meet the threshold — check the original criteria.
Score a point for chronic hepatic disease (cirrhosis) OR biochemical evidence of significant hepatic derangement (bilirubin >2× ULN with AST/ALT/ALP >3× ULN). Mild liver enzyme elevations don't count.
Major bleeding means requiring hospitalization, hemoglobin drop ≥2 g/dL, and/or transfusion. GI bleeds, intracranial hemorrhage, and major trauma bleeds all count. Minor bruising does not.
You can't change a patient's age, but you can ensure elderly patients (>65) have fall prevention in place, avoid concurrent NSAIDs, and have closer INR monitoring if on warfarin.
If a patient starts with HAS-BLED 4 and you control their BP, stop their NSAID, and improve TTR, they might drop to HAS-BLED 2. Show patients the score can improve with effort.
Aspirin doesn't prevent stroke effectively in AFib and still carries bleeding risk. Current guidelines recommend against aspirin monotherapy for AFib stroke prevention. It's anticoagulation or nothing.
Recording HAS-BLED alongside [CHA2DS2-VASc](/tools/cha2ds2-vasc) demonstrates you've considered bleeding risk. It protects you medicolegally and ensures the next provider sees your risk assessment.
HAS-BLED was developed by Pisters et al. (Chest 2010) from the Euro Heart Survey on Atrial Fibrillation. It is endorsed by ESC (2020) and NICE guidelines. Studies confirm net clinical benefit of anticoagulation even in high HAS-BLED patients when CHA2DS2-VASc indicates stroke risk (Olesen et al., JACC 2011).
Your HAS-BLED score ranges from 0 to 9 and estimates the 1-year risk of major bleeding in patients with atrial fibrillation on anticoagulation. A score of 0 corresponds to a major bleeding risk of approximately 1.13% per year. A score of 1 carries roughly 1.02% risk, and a score of 2 carries approximately 1.88% risk. A score of 3 or higher is classified as high risk, with bleeding rates of 3.74% and above, increasing with each additional point.
Critically, a high HAS-BLED score does not mean anticoagulation should be withheld. Studies consistently show that patients with both high CHA₂DS₂-VASc and high HAS-BLED scores derive net clinical benefit from anticoagulation. The score's primary purpose is to identify patients who need closer monitoring and correction of modifiable bleeding risk factors.
Use this calculator alongside the CHA₂DS₂-VASc score whenever evaluating anticoagulation therapy in a patient with atrial fibrillation. It should be assessed at the time of initiating anticoagulation, during follow-up visits, and whenever a patient's clinical status changes — for example, new onset of uncontrolled hypertension, initiation of antiplatelet therapy or NSAIDs, or a change in alcohol consumption.
The score is also useful for structuring conversations with patients about the risks and benefits of anticoagulation. Identifying modifiable risk factors (uncontrolled blood pressure, labile INR, concurrent antiplatelet or NSAID use, excessive alcohol) provides actionable targets to reduce bleeding risk while maintaining anticoagulation.
The HAS-BLED score was developed and validated primarily in patients taking vitamin K antagonists (warfarin), where labile INR is a relevant risk factor. For patients on direct oral anticoagulants (DOACs), the labile INR criterion does not apply, and the score may be less calibrated. Some experts suggest assigning 0 for labile INR in DOAC users, but this has not been formally validated.
The score treats all risk factors equally (1 point each), which may not reflect the true relative contribution of each factor to bleeding risk. A patient with active liver disease and a history of major hemorrhage is likely at substantially higher risk than a patient whose only points come from age over 65 and moderate alcohol use. Additionally, the score does not capture certain bleeding risk factors such as thrombocytopenia, concurrent use of other anticoagulants, or recent falls history in elderly patients. Clinical judgment remains essential.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.
CardiologyCalculate the HEART Score to assess the risk of major adverse cardiac events (MACE) in patients presenting with chest pain.